Check-Cap's C-Scan ingestible capsule gains CE mark approval for colorectal cancer screening

Check-Cap announced Wednesday that it received CE mark approval for the C-Scan system, an ingestible capsule for preparation-free colorectal cancer screening. CEO Bill Densel remarked that the approval "is a key validation of C-Scan and its potential as a convenient and comfortable option for identifying polyps in the colon." He added that the company remains on target to commence post-approval and pilot studies in the EU and US, respectively, in the first half of this year.

According to Check-Cap, the C-Scan system offers an alternative to existing colon cancer screening methods requiring laxative preparation and endoscopic procedures. "C-Scan is designed to improve the patient experience and increase the number of adults screened by eliminating procedural requirements frequently cited as barriers to adherence to screening guidelines such as bowel preparation, fasting and sedation," the company added.

Check-Cap noted that the fully autonomous system features "an ingestible, ultra-low dose X-ray capsule combined with a state-of-the-art wireless tracking system," allowing structural information on the colon's lumen to be generated. Check-Cap explained that the information is then used to create 2D and 3D maps of the colon, which enable doctors to identify pre-cancerous polyps and other abnormalities. 

Did you like this article?